EFFECT OF IVABRADINE COMBINED WITH METOPROLOL ON SERUM GAL-3, CTNI LEVELS, AND CARDIAC STRUCTURE AND FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE

Jiafeng Yin, Xiaokang Wu, Yan Geng, Qian He, Jianhong Zhu, Hailong Liu, Ting Zhang, Hao Meng, Zhi Guo, Huange Zhu, Miaoxian Li, Bo Yang^*

Department of Clinical Laboratory, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China

Objective: To explore the effect of ivabradine combined with metoprolol on serum Gal-3 and cTnI levels and cardiac structure and function in patients with chronic heart failure (CHF).

Methods: 142 CHF patients at our hospital from February 2020 to March 2021 were randomly divided into an observation group (n = 71) and a control group (n = 71). The control group was treated with metoprolol sustained-release tablets, and the observation group was treated with ivabradine on the basis of the control group. The effective rate, the incidence of adverse reactions, the levels of Gal-3, cTnI, and B-type brain natriuretic peptide (BNP), and the improvement of NYHA cardiac function were compared between the two groups before and after treatment.

Results: Compared with the total effective rate of 76.06% (54/71) in the control group, the total effective rate of 91.55% (65/71) in the observation group represented a significant increase (P<0.05). Compared with levels prior to treatment, the levels of Gal-3, cTnI, and BNP in the two groups were significantly decreased following treatment (P<0.05); compared with the control group, the levels of Gal-3, cTnI, and BNP in the observation group were significantly decreased (P<0.05). Compared with conditions prior to treatment, LVESD and LVEDd in the two groups were significantly decreased, while LVEF was significantly increased (P<0.05); compared with the control group following treatment, LVESD and LVEDd in the observation group were significantly decreased, while LVEF was significantly increased (P<0.05). Compared with grades prior to treatment, the cardiac function grades of the two groups were significantly improved after treatment (P<0.05); following treatment, the improvement of cardiac function classification in the observation group was more significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group: 8.45% (6/71) vs 7.04% (5/71) (P>0.05).

Conclusion: The effect of ivabradine combined with metoprolol in the treatment of CHF patients is ideal—the combination can significantly improve their cardiac function and reduce the levels of Gal-3, cTnI, and BNP in serum, with high safety and reliability.